Ow-up will be needed to determine whether HCV cure through the use of direct-acting antivirals among HIV/ HCV coinfected elite controllers will make the risk for complications among these patients similar to their HIV monoinfected counterparts. Further studies will also be needed to determine the effects of antiretroviral therapy in this group of patients coupled to its risk/benefit ratio. Whereas